Biogen Corp - רווח נקי למניה אחת בשנים עשר החודשים האחרונים BIIB

Biogen Inc. (BIIB) is shifting its focus toward combating Alzheimer's disease through mergers and risk-taking. Stable revenue from sclerosis therapy supports the company, while the annual percentage growth of EPS TTM helps identify the real development trend, where -78.20 serves as the current parameter value. However, a high probability of R&D failure and pressure from generics pose serious threats to business margins.

Year-over-year EPS growth (TTM) measures the percentage change in net income per share over a rolling twelve-month period, reflecting the actual efficiency of capital generation. By analyzing the annual net income per share growth rate (TTM) on the GURU.Markets platform, investors assess business resilience relative to the sector. The current value of -78.20 allows for the verification of Biogen Inc. (BIIB)'s ability to monetize scientific developments. This is critically important, as the high costs of developing neurological drugs often lead to sharp earnings volatility.